-
Indian Journal of Pediatrics Feb 2013
Topics: Dexamethasone; Humans; Infant, Newborn; Meningitis, Bacterial
PubMed: 23355014
DOI: 10.1007/s12098-013-0975-1 -
Archives of Disease in Childhood Mar 1993
Review
Topics: Bronchopulmonary Dysplasia; Dexamethasone; Drug Administration Schedule; Humans; Infant, Newborn; Infant, Premature
PubMed: 8466274
DOI: 10.1136/adc.68.3_spec_no.330 -
Aesthetic Plastic Surgery Oct 2020Rhinoplasty is one of the most challenging cosmetic surgical operations. The procedure has been known to precipitate higher levels of edema and ecchymosis in the... (Meta-Analysis)
Meta-Analysis
BACKGROUND
Rhinoplasty is one of the most challenging cosmetic surgical operations. The procedure has been known to precipitate higher levels of edema and ecchymosis in the periorbital and paranasal regions. The literature recommends the use of corticosteroids such as dexamethasone to alleviate these postoperative morbidities. In this review, we aim to provide a current state of evidence concerning the influence of dexamethasone together with rhinoplasty on intraoperative and postoperative morbidities.
METHODS
A systematic identification of the literature was performed according to PRISMA guidelines on four academic databases: MEDLINE, Scopus, EMBASE and CENTRAL. A meta-analysis compared the influence of dexamethasone and normal saline administered during rhinoplasty on the amount of intraoperative blood loss, postoperative edema and ecchymosis.
RESULTS
Out of 1045 records, ten articles including 374 participants (mean age: 25.8 ± 2.5 years) were included in this review. This systematic review presents a 1b level of evidence supporting the use of dexamethasone during rhinoplasty to reduce the amount of intraoperative blood loss, edema and ecchymosis as compared to normal saline. The meta-analysis reveals beneficial effects for dexamethasone interventions by demonstrating medium to large effect reduction of the amount of intraoperative blood loss (Hedge's g: - 0.69), mean edema score (- 1.09) and mean ecchymosis score (- 1.03) as compared to placebo groups using normal saline.
CONCLUSION
The current systematic review and meta-analysis recommend the administration of dexamethasone with rhinoplasty. The review reports beneficial effects of dexamethasone's administration as compared to normal saline for reducing the amount of intraoperative blood loss, postoperative edema and ecchymosis.
LEVEL OF EVIDENCE III
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Topics: Adult; Dexamethasone; Ecchymosis; Edema; Humans; Postoperative Complications; Rhinoplasty; Young Adult
PubMed: 32383002
DOI: 10.1007/s00266-020-01743-w -
Biomedical Chromatography : BMC May 2021Dexamethasone acetate (DEX), a potent anti-inflammatory, is used primarily in the treatment of inflammatory and autoimmune diseases. It was incorporated in CETETH 20...
Dexamethasone acetate (DEX), a potent anti-inflammatory, is used primarily in the treatment of inflammatory and autoimmune diseases. It was incorporated in CETETH 20 (polyoxyethylene 20 cetyl alcohol)-based liquid crystalline systems to enhance the purpose of the drug. Concomitant with the pharmaceutical technology performed, a HPLC method was developed and validated for the quantification of dexamethasone acetate in CETETH 20-based liquid crystalline systems for the evaluation of the drug in the new matrix. The method was performed using a C18 column with acetonitrile:methanol:water (35:35:30, v/v/v) as the mobile phase at a flow rate of 0.8 mL min at 239 nm. The method was linear in the range of 1-25 μg mL ; the limit of quantification and limit of detection were 0.05 and 0.16 μg mL , respectively; the accuracy of the method was 99.92% (relative standard deviation < 1%), and it presented intra-day and inter-day precision with deviations less than 1%. In this context, the method was successfully used to determine the incorporation efficiency of DEX in CETETH 20-based liquid crystalline systems and can be easily used by pharmaceutical companies and laboratories around the world.
Topics: Anti-Inflammatory Agents; Chromatography, High Pressure Liquid; Dexamethasone; Liquid Crystals
PubMed: 33314174
DOI: 10.1002/bmc.5054 -
Lancet (London, England) Apr 1971
Topics: Dexamethasone; Encephalitis; Herpes Simplex; Humans
PubMed: 4101446
DOI: 10.1016/s0140-6736(71)92010-1 -
The Journal of Infectious Diseases Apr 1989
Clinical Trial
Topics: Brain Diseases; Dexamethasone; Humans; Malaria
PubMed: 2926173
DOI: 10.1093/infdis/159.4.803 -
International Journal of Molecular... Nov 2023Many treatments for autoimmune diseases, caused by the loss of immune self-tolerance, are broadly immunosuppressive. Dendritic cells (DCs) can be induced to develop...
Many treatments for autoimmune diseases, caused by the loss of immune self-tolerance, are broadly immunosuppressive. Dendritic cells (DCs) can be induced to develop anti-inflammatory/tolerogenic properties to suppress aberrant self-directed immunity by promoting immune tolerance in an antigen-specific manner. Dexamethasone can generate tolerogenic DCs and upregulates MERTK expression. As MERTK can inhibit inflammation, we investigated whether dexamethasone's tolerogenic effects are mediated via MERTK, potentially providing a novel therapeutic approach. Monocyte-derived DCs were treated with dexamethasone, and with and without MERTK ligands or MERTK inhibitors. Flow cytometry was used to assess effects of MERTK modulation on co-stimulatory molecule expression, efferocytosis, cytokine secretion and T cell proliferation. The influence on expression of Rab17, which coordinates the diversion of efferocytosed material away from cell surface presentation, was assessed. Dexamethasone-treated DCs had upregulated MERTK expression, decreased expression of co-stimulatory molecules, maturation and proliferation of co-cultured T cells and increased uptake of myelin debris. MERTK ligands did not potentiate these properties, whilst specific MERTK inhibition only reversed dexamethasone's effect on myelin uptake. Cells undergoing efferocytosis had higher Rab17 expression. Dexamethasone-enhanced efferocytosis in DCs is MERTK-dependent and could exert its tolerogenic effects by increasing Rab17 expression to prevent the presentation of efferocytosed material on the cell surface to activate adaptive immune responses.
Topics: c-Mer Tyrosine Kinase; Dendritic Cells; T-Lymphocytes; Immunosuppressive Agents; Immune Tolerance; Dexamethasone
PubMed: 37958886
DOI: 10.3390/ijms242115903 -
Steroids Feb 2014Inhaled glucocorticoid dexamethasone is the most effective treatment of asthma currently available. Epithelial damage and shedding represents a clear manifestation of...
Inhaled glucocorticoid dexamethasone is the most effective treatment of asthma currently available. Epithelial damage and shedding represents a clear manifestation of asthmatic pathologies. However it remains unknown if dexamethasone regulates functions of airway progenitor cells that are responsible for epithelial repair. In present study Secretoglobin1a1 (Scgb1a1) lineage tracing mice were injected intraperitoneally with tamoxifen to induce the expression of green fluorescence protein (GFP) in Scgb1a1-expressing conducting airway progenitor cells. Scgb1a1-expressing progenitor cells were isolated from lungs of Scgb1a1 lineage tracing mice via flow activated cell sorting. In vitro three-dimensional matrigel culture of these progenitor cells revealed that dexamethasone has little effect on the colony forming ability of airway epithelial progenitor cells, but exhibits significant effects on the differentiation of the progenitor cells. Compared to the untreated group, dexamethasone treatment inhibited the expression of forkhead box J1 (FoxJ1) and mucin subtype A & C (Muc5Ac), but promoted the expression of calcium activated chloride channel 3 (Clca3) and cystic fibrosis transmembrane conductance regulator (Cftr). Dexamethasone-induced effects on the expression of FoxJ1, Muc5Ac and Clca3 were abolished or even reversed in the presence of RU486, an antagonist of glucocorticoid receptor, indicating that glucocorticoid receptor plays a role in the regulation of airway epithelial progenitor cells by dexamethasone. These data suggested that, though effective to reduce airway inflammation, dexamethasone treatment alone fails to fully restore the mucociliary clearance function in the treatment of asthma patients.
Topics: Animals; Cell Differentiation; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Epithelial Cells; Mice; Stem Cells; Structure-Activity Relationship; Trachea
PubMed: 24333449
DOI: 10.1016/j.steroids.2013.12.001 -
Veterinary Dermatology Dec 2022Background - Topical glucocorticoids commonly are used in the management of canine atopic dermatitis to control and prevent allergy flares. Compounding commercial...
Background - Topical glucocorticoids commonly are used in the management of canine atopic dermatitis to control and prevent allergy flares. Compounding commercial veterinary wipe/pad products to include dexamethasone sodium phosphate (Dex SP) can simplify treatment protocols for owners. Dex SP has not been evaluated for stability when added to wipes/pads. Hypothesis/objective - To evaluate the stability of Dex SP when compounded in three commercial veterinary wipe/pad products containing chlorhexidine. Methods and materials - Dex SP (Dexium, Bimeda; Oakbrook Terrace, IL, USA) was added to TrizCHLOR 4 wipes (TCL; Dechra Veterinary Products; Overland Park, KS, USA), KetoHex wipes (KH; VetOne; Boise, ID, USA), and DOUXO Chlorhexidine Pads (DCP; Ceva Animal Health; Lenexa, KS, USA), creating a 0.04% Dex SP solution. The concentration of Dex SP was measured in μg/mL/wipe or pad in triplicate at Day (D)0, D14 and D28 using liquid chromatography with tandem mass spectrometry. The amount of Dex SP at baseline (D0) was compared to the amount recovered at D14 and D28. Results - The amount of Dex SP in TCL and KH was unchanged between D0, D14 and D28. The amount of Dex SP recovered from DCP on D0 (mean 89.40 μg/mL/pad), D14 (mean 65.58 μg/mL/pad) and D28 (mean 68.09 μg/mL/pad) revealed a significant decline from D0 to D14 (P = 0.004). Conclusions and clinical importance - These data provide evidence that Dex SP is stable for 28 days in TCL and KH, and not in DCP from D0 to D14 or D28 days.
Topics: Animals; Dogs; Chlorhexidine; Dexamethasone; Glucocorticoids; Skin
PubMed: 35859527
DOI: 10.1111/vde.13108 -
Klinische Monatsblatter Fur... Apr 2024
Topics: Humans; Male; Anti-Inflammatory Agents; Dexamethasone; Drug Implants; Iatrogenic Disease; Intravitreal Injections; Retinal Hemorrhage; Aged, 80 and over
PubMed: 38653311
DOI: 10.1055/a-2282-3278